Combination Gene Therapy and Th1Th2 Therapy

联合基因疗法和 Th1Th2 疗法

• 批准号: 8553051
• 负责人: DANIEL FOWLER
• 金额: $ 33.61万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8553051
• 关键词: Agreement; Allogenic; Animal Model; Apoptosis; Area; Bone Marrow Transplantation; Cell physiology; Cells; Clinical Protocols; Combined Modality Therapy; Complication; Environment; Enzymes; Gene Delivery; Gene Transfer; Genes; Goals; Hematology; Hematopoietic Stem Cell Transplantation; Lentivirus Vector; Lymph; Modeling; Mutate; Non-Hodgkin' s Lymphoma; Organ Transplantation; Prodrugs; Proteins; Research; Resistance; Safety; Sirolimus; T cell therapy; T-Lymphocyte; Testing; Therapeutic; Tissues; Universities; Work; Zidovudine; cancer site; combination gene therapy; gene therapy; graft vs host disease; immuno-gene therapy; improved; in vivo; leukemia/lymphoma; medin; novel; suicide gene; therapeutic gene; tumor

We have focused our efforts on the use of lentiviral vectors to transfer genes to the rapamycin-resistant T cells. Using this approach, the majority of T cells in a given culture can be induced to express the new gene. We have also developed animal models to test the in vivo effect of these immuno-gene therapy strategies. Such models incorporate tumors and also evaluate graft-versus-host disease, which remains the main complication after allogeneic hematopoietic stem cell transplantation. To facilitate implementation of this project, we have entered into a cooperative research agreement with Lentigen Corporation to develop clinical protocols focusing on lentiviral delivery of suicide genes.Relevant cancer sites: Non-Hodgkins Lymphoma, Leukemia. Relevant Research Areas: Gene Therapy, Bone Marrow Transplantation, Organ Transplantation Research, Combined Treatment Modalities, Hematology/Lymph.

我们的重点是利用慢病毒载体将基因转移到雷帕霉素耐药的T细胞中。 使用这种方法，可以诱导给定培养物中的大多数 T 细胞表达新基因。 我们还开发了动物模型来测试这些免疫基因治疗策略的体内效果。 此类模型纳入肿瘤并评估移植物抗宿主病，这仍然是同种异体造血干细胞移植后的主要并发症。为了促进该项目的实施，我们与 Lentigen Corporation 签订了合作研究协议，开发专注于慢病毒递送自杀基因的临床方案。相关癌症部位：非霍奇金淋巴瘤、白血病。 相关研究领域：基因治疗、骨髓移植、器官移植研究、综合治疗方式、血液学/淋巴。